10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: During the United Kingdom Prospective Diabetes Study (UKPDS), patients with type 2 diabetes mellitus who received intensive glucose therapy had a lower risk of microvascular complications than did those receiving conventional dietary therapy. We conducted post-trial monitoring to determine whether this improved glucose control persisted and whether such therapy had a long-term effect on macrovascular outcomes. METHODS: Of 5102 patients with newly diagnosed type 2 diabetes, 4209 were randomly assigned to receive either conventional therapy (dietary restriction) or intensive therapy (either sulfonylurea or insulin or, in overweight patients, metformin) for glucose control. In post-trial monitoring, 3277 patients were asked to attend annual UKPDS clinics for 5 years, but no attempts were made to maintain their previously assigned therapies. Annual questionnaires were used to follow patients who were unable to attend the clinics, and all patients in years 6 to 10 were assessed through questionnaires. We examined seven prespecified aggregate clinical outcomes from the UKPDS on an intention-to-treat basis, according to previous randomization categories. RESULTS: Between-group differences in glycated hemoglobin levels were lost after the first year. In the sulfonylurea-insulin group, relative reductions in risk persisted at 10 years for any diabetes-related end point (9%, P=0.04) and microvascular disease (24%, P=0.001), and risk reductions for myocardial infarction (15%, P=0.01) and death from any cause (13%, P=0.007) emerged over time, as more events occurred. In the metformin group, significant risk reductions persisted for any diabetes-related end point (21%, P=0.01), myocardial infarction (33%, P=0.005), and death from any cause (27%, P=0.002). CONCLUSIONS: Despite an early loss of glycemic differences, a continued reduction in microvascular risk and emergent risk reductions for myocardial infarction and death from any cause were observed during 10 years of post-trial follow-up. A continued benefit after metformin therapy was evident among overweight patients. (UKPDS 80; Current Controlled Trials number, ISRCTN75451837.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The potential risks of intensive glycemic control may be obviated by incorporating agents that are not associated with hypoglycemia, especially in persons with frequent severe hypoglycemia, hypoglycemia unawareness, or a very long duration of DM, and particularly in the presence of established and advanced atherosclerosis, advanced age, and terminal illness.69,70,76–81”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [79]
In the citing paper
“it is worth noting the legacy effects of significant, early glucose lowering on macrovascular and microvascular complications observed in the UKPDS study [3,37].”
In the citing paper
“Although recidivism in glycemia is typically observed across all interventions in diabetes [4,5,6,29] including pharmaceutical interventions [3,37]”
In the citing paper
“Numerous studies have demonstrated the clinical benefits of early achievement of nearnormal glycemic control in individuals with type 1 diabetes and type 2 diabetes (77-83).”
From Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range (2019) · cites this paper as [81]
In the citing paper
“since optimal glycaemic control reduces the risk of both microvascular and macrovascular complications (36, 55).”
From Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus (2024) · cites this paper as [55]
31 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationEuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Research works printed but not linked: 3
- 1959, Stat Bull Metrop Insur Co, 40, 1
- Nathan DM, 2005, N Engl J Med, 22, 2643
- 1993, N Engl J Med, 329, 997
Cited by
Items 201–300 of 1,169
Thompson, A., Fleischmann, K. E., Smilowitz, N. R., de las Fuentes, L., Mukherjee, D., Aggarwal, N. R., Ahmad, F. S., Allen, R. B., Altin, S. E., Auerbach, A., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001285 · Cited by 365
Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency
Lipska, K. J., Bailey, C. J., & Inzucchi, S. E. (2011) · Diabetes Care · doi:10.2337/dc10-2361 · Cited by 432
Nanayakkara, N., Curtis, A. J., Heritier, S., Gadowski, A. M., Pavkov, M. E., Kenealy, T., Owens, D. R., Thomas, R. L., Song, S., Wong, J., et al. (2021) · Diabetologia · doi:10.1007/s00125-020-05319-w · Cited by 393
Bushnell, C., Kernan, W. N., Sharrief, A. Z., Chaturvedi, S., Cole, J. W., Cornwell, W. K., Cosby-Gaither, C., Doyle, S., Goldstein, L. B., Lennon, O., et al. (2024) · Stroke · doi:10.1161/str.0000000000000475 · Cited by 360
Vascular Complications of Diabetes
Beckman, J. A., & Creager, M. A. (2016) · Circulation Research · doi:10.1161/circresaha.115.306884 · Cited by 412
“other diabetes mellitus medications, after the active portion of the study ended.(143) Other studies have supported the use”
ResultQaseem, A., Wilt, T. J., Kansagara, D., Horwitch, C., Barry, M. J., Forciea, M. A., & for the Clinical Guidelines Committee of the American College of Physicians* (2018) · Annals of Internal Medicine · doi:10.7326/m17-0939 · Cited by 412
“This trial showed that treatment to a target of about 7% with a sulfonylurea and insulin (if needed) in adults with newly diagnosed diabetes did not reduce risk for any diabetes-related end point or all-cause mortality after 10 years but was associated with a small absolute reduction in these outcomes after 17 years (…”
MethodArterburn, D. E., Bogart, A., Sherwood, N. E., Sidney, S., Coleman, K. J., Haneuse, S., O’Connor, P. J., Theis, M. K., Campos, G. M., McCulloch, D., et al. (2013) · Obesity Surgery · doi:10.1007/s11695-012-0802-1 · Cited by 426
Lin, B., Koibuchi, N., Hasegawa, Y., Sueta, D., Toyama, K., Uekawa, K., Ma, M., Nakagawa, T., Kusaka, H., & Kim-Mitsuyama, S. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0148-1 · Cited by 423
“Previous large clinical trials have established that strict glycemic control significantly reduces diabetic microvascular complications such as nephropathy or retinopathy [3-5].”
Ceriello, A., Ihnat, M. A., & Thorpe, J. E. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1824 · Cited by 413
“Data from the follow-up of the UKPDS have shown that type 2 diabetic patients, like type 1 diabetic patients in the DCCT-EDIC, who were on the standard treatment regimen during the study still have a higher incidence of microvascular and cardiovascular complications compared with their counterparts receiving intensive…”
MethodSteven, S., Hollingsworth, K. G., Al-Mrabeh, A., Avery, L., Aribisala, B., Caslake, M., & Taylor, R. (2016) · Diabetes Care · doi:10.2337/dc15-1942 · Cited by 418
“The effect of a period of normoglycemia confers substantial benefits in decreasing the risk of complications, even if hyperglycemia recurs (40).”
Schramm, T. K., Gislason, G. H., Vaag, A., Rasmussen, J. N., Folke, F., Hansen, M. L., Fosbøl, E. L., Køber, L., Norgaard, M. L., Madsen, M., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr077 · Cited by 418
“In the context of the suggested legacy effect of glucose-lowering agents in the 10-year follow-up of the UK Prospective Diabetes Study (UKPDS), the impact of the initial treatment in type 2 diabetes may be crucial in terms of long-term risk.(1) Primarily on the basis of the results of the UKPDS metformin substudy, met…”
BackgroundMetformin: Mechanisms in Human Obesity and Weight Loss
Yerevanian, A., & Soukas, A. A. (2019) · Current Obesity Reports · doi:10.1007/s13679-019-00335-3 · Cited by 414
Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial.
Rodbard, H. W., Lingvay, I., Reed, J., de la Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P.-L., Wijayasinghe, N., & Norwood, P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00070 · Cited by 412
Qureshi, A. I., & Caplan, L. R. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61088-0 · Cited by 395
Etxeberria, U., de la Garza, A. L., Campión, J., Martínez, J. A., & Milagro, F. I. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.664134 · Cited by 395
“These abnormalities could lead to lesions such as retinopathy, nephropathy, neuropathy and angiopathy [3].”
BackgroundAdvanced Glycation end Products, Oxidative Stress and Diabetic Nephropathy
Yamagishi, S.-I., & Matsui, T. (2010) · Oxidative Medicine and Cellular Longevity · doi:10.4161/oxim.3.2.11148 · Cited by 397
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
“Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.”
BackgroundGriffin, S. J., Leaver, J. K., & Irving, G. J. (2017) · Diabetologia · doi:10.1007/s00125-017-4337-9 · Cited by 398
“studies [19, 21] to 15 years [27]) and poorly controlled diabetes (average baseline HbA1c was less than 8% [63.”
BackgroundMethodInfluentialGlycemic control in youth with diabetes: the SEARCH for Diabetes in Youth Study
Petitti, D. B., Klingensmith, G. J., Bell, R. A., Andrews, J. S., Dabelea, D., Imperatore, G., Marcovina, S., Pihoker, C., Standiford, D., Waitzfelder, B., et al. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2009.05.025 · Cited by 397
Agiostratidou, G., Anhalt, H., Ball, D., Blonde, L., Gourgari, E., Harriman, K. N., Kowalski, A. J., Madden, P., McAuliffe-Fogarty, A. H., McElwee-Malloy, M., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1624 · Cited by 397
Diabetes: Advances in Diagnosis and Treatment
Nathan, D. M. (2015) · JAMA · doi:10.1001/jama.2015.9536 · Cited by 384
Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences
Gallo, L. A., Wright, E. M., & Vallon, V. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114561992 · Cited by 395
Taheri, S., Zaghloul, H., Chagoury, O., Elhadad, S., Ahmed, S. H., El Khatib, N., Amona, R. A., El Nahas, K., Suleiman, N., Alnaama, A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30117-0 · Cited by 393
Markers of and Risk Factors for the Development and Progression of Diabetic Kidney Disease
MacIsaac, R. J., Ekinci, E. I., & Jerums, G. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.10.048 · Cited by 378
Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes
Monnier, L., Colette, C., Wojtusciszyn, A., Dejager, S., Renard, E., Molinari, N., & Owens, D. R. (2017) · Diabetes Care · doi:10.2337/dc16-1769 · Cited by 390
“in the pathogenesis of all related complications from diabetes, both in type 1 (1,2) and type 2 diabetes (3,4).”
BackgroundIndividualizing Glycemic Targets in Type 2 Diabetes Mellitus: Implications of Recent Clinical Trials
Ismail-Beigi, F., Moghissi, E., Tiktin, M., Hirsch, I. B., Inzucchi, S. E., & Genuth, S. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-8-201104190-00007 · Cited by 386
“The results, similar to those of the DCCT (Diabetes Control and Complications Trial) (8) in patients with type 1 diabetes mellitus, demonstrated that intensive therapy delayed the onset and reduced the progression of albuminuria and retinopathy but did not decrease the risk for myocardial infarction (MI).”
BackgroundInfluentialCefalu, W. T., Kaul, S., Gerstein, H. C., Holman, R. R., Zinman, B., Skyler, J. S., Green, J. B., Buse, J. B., Inzucchi, S. E., Leiter, L. A., et al. (2018) · Diabetes Care · doi:10.2337/dci17-0057 · Cited by 363
Self-citationHemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T., Hemmingsen, C., & Wetterslev, J. (2011) · BMJ · doi:10.1136/bmj.d6898 · Cited by 386
Fox, C. S., Golden, S. H., Anderson, C., Bray, G. A., Burke, L. E., de Boer, I. H., Deedwania, P., Eckel, R. H., Ershow, A. G., Fradkin, J., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000230 · Cited by 386
“01) reduction in MI became significant only after 10 years of observational follow-up of the UKPDS population, despite the convergence of mean A 1c soon after the randomized component of the study ended.(135) Three large trials in type 2 diabetes mellitus were designed to address continuing uncertainty(136) about the…”
Khunti, K., Gomes, M. B., Pocock, S., Shestakova, M. V., Pintat, S., Fenici, P., Hammar, N., & Medina, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13088 · Cited by 367
“Several studies have identified two main reasons for suboptimal glycaemic control in clinical practice: (1) patient non-adherence to prescribed treatment and (2) clinical or therapeutic inertia, defined as the failure to initiate or intensify therapy in a timely manner according to evidence-based clinical guidelines i…”
BackgroundShea, S., Weinstock, R. S., Teresi, J. A., Palmas, W., Starren, J., Cimino, J. J., Lai, A. M., Field, L., Morin, P. C., Goland, R., et al. (2009) · Journal of the American Medical Informatics Association · doi:10.1197/jamia.m3157 · Cited by 379
“Longterm follow-up in the UKPDS showed significant reductions in microvascular and macrovascular disease as well as death with better glycemic control.(35) The current consensus is that prudent glycemic control remains desirable for most people with diabetes, with a target HgbA1c 7%, which should be adjusted upwardly…”
Tomita, I., Kume, S., Sugahara, S., Osawa, N., Yamahara, K., Yasuda-Yamahara, M., Takeda, N., Chin-Kanasaki, M., Kaneko, T., Mayoux, E., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.06.020 · Cited by 376
Marwick, T. H., Hordern, M. D., Miller, T., Chyun, D. A., Bertoni, A. G., Blumenthal, R. S., Philippides, G., & Rocchini, A. (2009) · Circulation · doi:10.1161/circulationaha.109.192521 · Cited by 370
Gupta, S., Dominguez, M., & Golestaneh, L. (2023) · Medical Clinics of North America · doi:10.1016/j.mcna.2023.03.004 · Cited by 337
Hong, J., Zhang, Y., Lai, S., Lv, A., Su, Q., Dong, Y., Zhou, Z., Tang, W., Zhao, J., Cui, L., et al. (2013) · Diabetes Care · doi:10.2337/dc12-0719 · Cited by 366
Wilding, J. P. H., Norwood, P., T'joen, C., Bastien, A., List, J. F., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc09-0517 · Cited by 363
Muzurović, E., Mikhailidis, D. P., & Mantzoros, C. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154770 · Cited by 336
Roussel, R. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.409 · Cited by 361
Systematic review: glucose control and cardiovascular disease in type 2 diabetes
Kelly, T. N., Bazzano, L. A., Fonseca, V. A., Thethi, T. K., Reynolds, K., & He, J. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-6-200909150-00137 · Cited by 358
“This issue is relevant in light of the finding that myocardial infarction and mortality were reduced on long-term follow-up of the UKPDS intensive therapy cohort (10, 11).”
Hyperglycemia: a prothrombotic factor?
LEMKES, B. A., HERMANIDES, J., DEVRIES, J. H., HOLLEMAN, F., MEIJERS, J. C. M., & HOEKSTRA, J. B. L. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03910.x · Cited by 346
Fernandez, A., Schillinger, D., Warton, E. M., Adler, N., Moffet, H. H., Schenker, Y., Salgado, M. V., Ahmed, A., & Karter, A. J. (2011) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1507-6 · Cited by 334
“Seventh, while we used a single measure of glycemic control, studies suggest that a single glycemic value can predict microsvascular events(46) and that exposure to poor control can impart a lasting “legacy effect” on microvascular and macrovascular events years after glycemic control equalizes between groups.(47) Thi…”
MethodGlycemic control and complications in type 2 diabetes mellitus
Stolar, M. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.004 · Cited by 356
Khunti, K., Davies, M., Majeed, A., Thorsted, B. L., Wolden, M. L., & Paul, S. K. (2015) · Diabetes Care · doi:10.2337/dc14-0920 · Cited by 356
Self-citationTherapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials
Calcutt, N. A., Cooper, M. E., Kern, T. S., & Schmidt, A. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2476 · Cited by 352
Hemostasis, endothelial stress, inflammation, and the metabolic syndrome
Grandl, G., & Wolfrum, C. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-017-0666-5 · Cited by 335
“inmicrovascular risk and small decreases of all-cause mortality over 10 years, suggesting that glucose alone is not sufficient to explain these effects [97, 98].”
BackgroundNyenwe, E. A., Jerkins, T. W., Umpierrez, G. E., & Kitabchi, A. E. (2011) · Metabolism · doi:10.1016/j.metabol.2010.09.010 · Cited by 343
Raz, I., Wilson, P. W. F., Strojek, K., Kowalska, I., Bozikov, V., Gitt, A. K., Jermendy, G., Campaigne, B. N., Kerr, L., Milicevic, Z., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1671 · Cited by 351
Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Diabetes Care · doi:10.2337/dci23-0036 · Cited by 351
“Long-term follow-up of the United Kingdom Prospective Diabetes Study (UKPDS) population supported a benefit of intensive therapy on macrovascular disease (49), but three other recent trials failed to demonstrate a significant difference in macrovascular disease outcomes between very intensive treatment strategies, whi…”
Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.191305 · Cited by 348
Japanese Clinical Practice Guideline for Diabetes 2019
Araki, E., Goto, A., Kondo, T., Noda, M., Noto, H., Origasa, H., Osawa, H., Taguchi, A., Tanizawa, Y., Tobe, K., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13306 · Cited by 341
Gallwitz, B., Rosenstock, J., Rauch, T., Bhattacharya, S., Patel, S., von Eynatten, M., Dugi, K. A., & Woerle, H.-J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60691-6 · Cited by 343
Contributions of risk factors and medical care to cardiovascular mortality trends
Ezzati, M., Obermeyer, Z., Tzoulaki, I., Mayosi, B. M., Elliott, P., & Leon, D. A. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.82 · Cited by 338
Ornoy, A., Reece, E. A., Pavlinkova, G., Kappen, C., & Miller, R. K. (2015) · Birth Defects Research Part C: Embryo Today: Reviews · doi:10.1002/bdrc.21090 · Cited by 313
“The UKPDS followed participants for a 10year post-trial monitoring study and found that those under stringent glucose control through use of insulin, insulin analogues, or anti-hyperglycemic therapies had 9% reduced risk for any diabetes complications, 24% reduced risk for microvascular disease, and 33% reduced risk o…”
MethodDiabetes and peripheral artery disease: A review
Soyoye, D. O., Abiodun, O. O., Ikem, R. T., Kolawole, B. A., & Akintomide, A. O. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i6.827 · Cited by 272
Peripheral arterial disease in diabetes—a review
Jude, E. B., Eleftheriadou, I., & Tentolouris, N. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02866.x · Cited by 320
Fishman, S. L., Sonmez, H., Basman, C., Singh, V., & Poretsky, L. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0060-3 · Cited by 330
“…in patients with both type 1 and type 2 DM correlating with duration of intensive glycemic control (Diabetes, C., I. Complications Trial /epidemiology of diabetes, and G. complications study research, 2016; Diabetes et al., 2015; Martin et al., 2014; Holman et al., 2008a; Holman et al., 2008b).”
BackgroundMetformin: a review of its potential indications
Wang, Y.-W., He, S.-J., Feng, X., Cheng, J., Luo, Y.-T., Tian, L., & Huang, Q. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s141675 · Cited by 320
“Compared with sulfonylurea and insulin treatment, metformin treatment can effectively reduce the risk of myocardial infarction and death.(71) Similarly, Roumie et al also showed that compared with sulfonylurea therapy, metformin treatment was associated with a decreased hazard of cardiovascular disease events or death…”
Rajamani, K., Colman, P. G., Li, L. P., Best, J. D., Voysey, M., D'Emden, M. C., Laakso, M., Baker, J. R., & Keech, A. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60698-x · Cited by 328
“Patients with only minor amputations also had significantly lower mean systolic blood pressure (142 mm Hg [SD 12] vs 148 mm Hg [18], p=0·043), a lower occurrence of previous cardiovascular disease (31 [48%] vs 36 [72%], p=0·009), and higher mean concentration of plasma LDL cholesterol (3·1 mmol/ L [0·6] vs 2·9 mmol/L…”
Biomarkers in Diabetic Retinopathy
Jenkins, A. J., Joglekar, M. V., Hardikar, A. A., Keech, A. C., O'Neal, D. N., & Januszewski, A. S. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.159 · Cited by 296
“It was demonstrated that prior intensive HbA1c control reduced risk of a composite microvascular end-point by 24%; retinopathy-specific data were not provided [49].”
BackgroundKeating, S. T., & El-Osta, A. (2015) · Circulation Research · doi:10.1161/circresaha.116.303936 · Cited by 317
“mia, such that vascular complications continue to develop despite more than a decade of blood glucose normalization.(11,12)”
BackgroundThe Evidence for Medical Nutrition Therapy for Type 1 and Type 2 Diabetes in Adults
Franz, M. J., Powers, M. A., Leontos, C., Holzmeister, L. A., Kulkarni, K., Monk, A., Wedel, N., & Gradwell, E. (2010) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2010.09.014 · Cited by 306
Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 302
(2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70156-1 · Cited by 319
Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, W. M. M., Albus, C., Benlian, P., Boysen, G., Cifkova, R., et al. (2012) · International Journal of Behavioral Medicine · doi:10.1007/s12529-012-9242-5 · Cited by 311
“Most patients in the UKPDS were followed for a further 10 years of post-trial observational monitoring.(444) No attempt was made to maintain previously assigned therapies and the glycaemic control in the two groups rapidly converged.”
Santos, F. L., Esteves, S. S., da Costa Pereira, A., Yancy Jr, W. S., & Nunes, J. P. L. (2012) · Obesity Reviews · doi:10.1111/j.1467-789x.2012.01021.x · Cited by 318
Yapanis, M., James, S., Craig, M. E., O’Neal, D., & Ekinci, E. I. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac034 · Cited by 291
Japanese Clinical Practice Guideline for Diabetes 2016
Haneda, M., Noda, M., Origasa, H., Noto, H., Yabe, D., Fujita, Y., Goto, A., Kondo, T., & Araki, E. (2018) · Diabetology International · doi:10.1007/s13340-018-0345-3 · Cited by 319
Adipose tissue retains an epigenetic memory of obesity after weight loss
Hinte, L. C., Castellano-Castillo, D., Ghosh, A., Melrose, K., Gasser, E., Noé, F., Massier, L., Dong, H., Sun, W., Hoffmann, A., et al. (2024) · Nature · doi:10.1038/s41586-024-08165-7 · Cited by 269
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes
Perkovic, V., Heerspink, H. L., Chalmers, J., Woodward, M., Jun, M., Li, Q., MacMahon, S., Cooper, M. E., Hamet, P., Marre, M., et al. (2013) · Kidney International · doi:10.1038/ki.2012.401 · Cited by 316
Standards of care for type 2 diabetes in China
Weng, J., Ji, L., Jia, W., Lu, J., Zhou, Z., Zou, D., Zhu, D., Chen, L., Chen, L., Guo, L., et al. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2827 · Cited by 315
“The long-term follow-up studies of the DCCT and UKPDS patient populations indicated that early intensive glycaemic control was correlated with a reduction in diabetic microvascular diseases and a significant decrease in the risks of myocardial infarction and death [26,27].”
BackgroundHenry, R. R., Murray, A. V., Marmolejo, M. H., Hennicken, D., Ptaszynska, A., & List, J. F. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02911.x · Cited by 310
The importance of weight management in type 2 diabetes mellitus
Wilding, J. P. H. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12384 · Cited by 314
Ueki, K., Sasako, T., Okazaki, Y., Kato, M., Okahata, S., Katsuyama, H., Haraguchi, M., Morita, A., Ohashi, K., Hara, K., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30327-3 · Cited by 313
Glucose Control and Diabetic Neuropathy: Lessons from Recent Large Clinical Trials
Ang, L., Jaiswal, M., Martin, C., & Pop-Busui, R. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0528-7 · Cited by 303
Yamagishi, S.-I. (2011) · Experimental Gerontology · doi:10.1016/j.exger.2010.11.007 · Cited by 302
Paul, S. K., Klein, K., Thorsted, B. L., Wolden, M. L., & Khunti, K. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0260-x · Cited by 298
“cause [8].”
Self-citationSilva, P. S., Cavallerano, J. D., Sun, J. K., Soliman, A. Z., Aiello, L. M., & Aiello, L. P. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.05.004 · Cited by 303
9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes
Lipska, K. J., Krumholz, H., Soones, T., & Lee, S. J. (2016) · JAMA · doi:10.1001/jama.2016.0299 · Cited by 309
Pearson-Stuttard, J., Zhou, B., Kontis, V., Bentham, J., Gunter, M. J., & Ezzati, M. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30150-5 · Cited by 307
RetractedHeart failure: a cardiovascular outcome in diabetes that can no longer be ignored
McMurray, J. J. V., Gerstein, H. C., Holman, R. R., & Pfeffer, M. A. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70031-2 · Cited by 304
Self-citationArnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
Cardiovascular Complications of Diabetic Kidney Disease
Pálsson, R., & Patel, U. D. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.03.003 · Cited by 292
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
Abdul-Ghani, M., Del Prato, S., Chilton, R., & DeFronzo, R. A. (2016) · Diabetes Care · doi:10.2337/dc16-0041 · Cited by 295
“Intensive glycemic control failed to decrease CV events in the UK Prospective Diabetes Study (UKPDS) (3), Action to Control Cardiovascular Risk in Diabetes (ACCORD) study (4), Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) study (5), and Veterans Affairs Diabetes Tri…”
BackgroundMethodInfluentialDavies, M. J., Gagliardino, J. J., Gray, L. J., Khunti, K., Mohan, V., & Hughes, R. (2013) · Diabetic Medicine · doi:10.1111/dme.12128 · Cited by 294
Yamagishi, S.-I., Maeda, S., Matsui, T., Ueda, S., Fukami, K., & Okuda, S. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.03.014 · Cited by 294
Satoh, H., Ohira, T., Hosoya, M., Sakai, A., Watanabe, T., Ohtsuru, A., Kawasaki, Y., Suzuki, H., Takahashi, A., Kobashi, G., et al. (2015) · Journal of Diabetes Research · doi:10.1155/2015/415253 · Cited by 302
SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheriadou, I., & Tentolouris, N. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16162965 · Cited by 300
DeFronzo, R. A., Lewin, A., Patel, S., Liu, D., Kaste, R., Woerle, H. J., & Broedl, U. C. (2015) · Diabetes Care · doi:10.2337/dc14-2364 · Cited by 296
“Maintaining intensive glucose control early in the disease process may lead to legacy benefits that persist beyond the period of treatment (4).”
BackgroundThe role of epigenetics in the pathology of diabetic complications
Villeneuve, L. M., & Natarajan, R. (2010) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00200.2010 · Cited by 295
“The United Kingdom Prospective Diabetes Study (UKPDS) found that lower fasting plasma glucose at the time of diagnosis correlated with decreased cardiovascular risk (31, 58), and The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial found that that i…”
BackgroundDiabetes and atherosclerosis: is there a role for hyperglycemia?
Chait, A., & Bornfeldt, K. E. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800059-jlr200 · Cited by 294
Macrovascular Complications in Patients with Diabetes and Prediabetes
Huang, D., Refaat, M., Mohammedi, K., Jayyousi, A., Al Suwaidi, J., & Abi Khalil, C. (2017) · BioMed Research International · doi:10.1155/2017/7839101 · Cited by 278
“However, a greater reduction of MI and overall mortality was observed in the metformin group compared to the sulfonylurea group at 5-year follow-up [70].”
ResultRusso, J. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1548 · Cited by 291
“Emergency 859 (268-1450) 641 (290-922) 1927 (936-2918) 1229 (721-1736) Laboratory and radiology 702 (495-909) 683 (530-835) 1542 (1203-1881) 1471 (1169-1773) Pharmacy 2714 (2071-3357) 2348 (1793-2904) 5801 (4606-6995) 5339 (4048-6630) Primary care 1085 (871-1299) 1216 (935-1498) 2366 (2001-2732) 2637 (2106-3168) Speci…”
Ferrannini, E., Fonseca, V., Zinman, B., Matthews, D., Ahrén, B., Byiers, S., Shao, Q., & Dejager, S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00994.x · Cited by 297
Self-citationLitwak, L., Goh, S.-Y., Hussein, Z., Malek, R., Prusty, V., & Khamseh, M. E. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-57 · Cited by 284
“Results of a 10-year follow-up study found that people with type 2 diabetes who maintain good glycaemic control experience benefits many years later, including lower rates of MI and diabetes-related death [2].”
BackgroundJadzinsky, M., Pfützner, A., Paz‐Pacheco, E., Xu, Z., Allen, E., Chen, R., & CV181‐039 Investigators (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01056.x · Cited by 296
Evaluating All Potential Oral Complications of Diabetes Mellitus
Verhulst, M. J. L., Loos, B. G., Gerdes, V. E. A., & Teeuw, W. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00056 · Cited by 276
Metformin: Is it a drug for all reasons and diseases?
Triggle, C. R., Mohammed, I., Bshesh, K., Marei, I., Ye, K., Ding, H., MacDonald, R., Hollenberg, M. D., & Hill, M. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155223 · Cited by 275
Vaccaro, O., Masulli, M., Nicolucci, A., Bonora, E., Del Prato, S., Maggioni, A. P., Rivellese, A. A., Squatrito, S., Giorda, C. B., Sesti, G., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30317-0 · Cited by 292
Preis, S. R., Pencina, M. J., Hwang, S.-J., D'Agostino, R. B., Savage, P. J., Levy, D., & Fox, C. S. (2009) · Circulation · doi:10.1161/circulationaha.108.846519 · Cited by 289
Metadata
- Authors
- Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W.
- Affiliations
- Churchill Hospital (GB)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- NIHR Oxford Biomedical Research Centre (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-10-09
- Volume
- 359
- Issue
- 15
- Pages
- 1577-1589
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2171294019
- Semantic Scholar
- 796f87021518c0bff851ff1ade5f780e3569e4ae
- Cited by
- 7,751
- References
- 55
- Citations by year
- 2026: 194 · 2025: 243 · 2024: 322 · 2023: 387 · 2022: 430 · 2021: 441 · 2020: 451 · 2019: 420 · 2018: 442 · 2017: 480 · 2016: 535 · 2015: 511 · 2014: 529 · 2013: 474 · 2012: 482
- FWCI
- 337.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- National Institute for Health and Care Research
- British Heart Foundation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, tight glycemic control, glycemic control, metformin, sulfonylureas, insulin therapy, dietary therapy, microvascular complications, macrovascular outcomes, myocardial infarction, mortality, HbA1c, post-trial follow-up, UKPDS
- MeSH terms
- Aged, Blood Glucose, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Myocardial Infarction, Risk, Sulfonylurea Compounds, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.